📄 medicine

Correlation between Triglyceride-Glucose Index and Clinical Features and Prognosis of Multiple Myeloma

This retrospective study of 60 multiple myeloma patients reveals that a higher baseline triglyceride-glucose (TyG) index is an independent risk factor for poorer overall survival, suggesting its potential utility as a simple, economical metabolic biomarker for prognosis.

Original authors: Jingyi Liu, Wanyi Sun, Yun Bai, Xingbin Dai

Published 2026-07-09

📖 4 min read☕ Coffee break read

CC BY 4.0

Original authors: Jingyi Liu, Wanyi Sun, Yun Bai, Xingbin Dai

Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). ✨ This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer

Imagine your body as a bustling city. Inside this city, there's a specific type of troublemaker called Multiple Myeloma (MM). It's a cancer of the blood cells that sets up shop in the bone marrow (the factory floor where blood is made). Doctors have been trying to predict how fast this troublemaker will grow and how long the city can survive using standard maps like the "Durie-Salmon" or "ISS" systems. These maps look at things like how many bad cells are in the factory or how much damage they've done to the buildings.

But sometimes, the standard maps miss something important: the energy grid of the city.

The New "Energy Meter": The TyG Index

This study introduces a new, simple tool called the Triglyceride-Glucose (TyG) Index. Think of this as a "fuel gauge" for your body's metabolism. It combines two numbers you likely already have from a routine blood test:

Triglycerides: The fat in your blood (like the oil in your engine).
Glucose: The sugar in your blood (like the gasoline).

When you mix these two together mathematically, you get a score that tells you how well your body is handling its fuel. A high score means your body is struggling to process sugar and fat efficiently (a state often called "insulin resistance").

What the Researchers Did

The researchers looked back at the medical records of 60 patients who had just been diagnosed with Multiple Myeloma. They didn't give them new treatments; they just checked their "fuel gauges" (TyG index) at the time of diagnosis and then watched to see what happened over time.

They split the patients into two groups:

The Low Fuel Group: Patients with a lower TyG score.
The High Fuel Group: Patients with a higher TyG score.

The Surprising Findings

Here is where the story gets interesting, and it's a bit like a detective story with a twist:

1. The "Dissociation" Mystery
Usually, you'd expect that if a patient has a lot of cancer cells, they would look very sick. But the researchers found something strange in the High Fuel Group:

They actually had fewer cancer cells in their bone marrow factories than the other group.
They also had better hemoglobin levels (meaning they had more healthy red blood cells).

By the old rules, these patients should have been doing better. They looked like the "low risk" group.

2. The Reality Check
Despite looking "healthier" on paper, the High Fuel Group had a much worse fate.

Survival (OS): Patients with a high TyG index were significantly more likely to pass away sooner. In fact, the study calculated that a high TyG score was a massive independent risk factor for death.
Progression (PFS): While they didn't find a statistically perfect link to how fast the disease grew (progression-free survival), the trend was still that the high-score group struggled more.

The Big Picture: Why Does This Happen?

The paper suggests a theory: The High TyG score isn't just about "bad numbers"; it represents a chaotic, inflammatory environment in the body.

Imagine the cancer cells are weeds. In the "Low Fuel" group, the soil is relatively calm. In the "High Fuel" group, the soil is on fire (due to metabolic inflammation and insulin resistance). Even if there are fewer weeds (cancer cells) at the start, the fiery soil makes those weeds grow faster, become tougher, and resist being pulled out. The cancer cells thrive in this messy, high-sugar, high-fat environment, making the disease more aggressive than the standard maps predicted.

The Conclusion

The paper concludes that the TyG index is a simple, cheap, and powerful "early warning system."

It can spot patients who might look "okay" on standard tests but are actually in a dangerous metabolic state.
It acts like a second pair of eyes, looking at the body's energy system rather than just counting the cancer cells.

Important Caveat: The authors are careful to say this is a small study (only 60 people) from one hospital. The "risk" number they calculated was huge, but because the group was small, it needs to be tested on thousands of people to be sure. However, the signal is clear: Metabolism matters. A body struggling to manage its sugar and fat might be a body where Multiple Myeloma is harder to fight.

Technical Summary: Correlation between Triglyceride-Glucose Index and Clinical Features and Prognosis of Multiple Myeloma

Problem Statement
Multiple Myeloma (MM) is the second most common hematologic malignancy, yet current prognostic staging systems (DS, ISS, R-ISS, R2-ISS) possess limitations, such as reliance on tumor burden alone, lack of cytogenetic data, or dependence on specialized testing like FISH. There is a clinical need for simple, economical novel markers to complement these systems. While metabolic disorders (glucose and lipid metabolism) are known to influence MM outcomes, the specific prognostic value of the Triglyceride-Glucose (TyG) index—a surrogate marker for insulin resistance integrating both metabolic pathways—has not been systematically investigated in MM patients.

Methodology
This study employed a single-center, retrospective cohort design involving 60 newly diagnosed MM patients treated at the Affiliated Hospital of Nanjing University of Chinese Medicine between January 2019 and June 2023.

Data Collection: Baseline data included demographics, disease characteristics, and laboratory results. The TyG index was calculated using the formula: $\ln[\text{fasting triglycerides (mg/dL)} \times \text{fasting glucose (mg/dL)} / 2]$ .
Stratification: Patients were divided into "High TyG" and "Low TyG" groups based on the cohort median TyG index of 8.49.
Statistical Analysis: Associations between the TyG index and clinical features were assessed using Mann-Whitney U, Chi-squared, or Fisher's exact tests. Overall Survival (OS) and Progression-Free Survival (PFS) were analyzed via Kaplan-Meier curves and log-rank tests. Univariate and multivariate Cox proportional hazards regression models were used to identify independent prognostic factors, adjusting for variables with $P < 0.10$ in univariate analysis and clinically relevant confounders (e.g., ISS stage, renal function, bone marrow plasma cell proportion).

Key Contributions
This research represents the first systematic introduction of the TyG index into MM prognostic research. Its primary contribution is the evaluation of the TyG index as a potential metabolic biomarker for risk stratification, aiming to provide a low-cost, accessible tool that complements existing staging systems.

Results

Clinical Correlations: Patients in the High TyG group exhibited significantly lower bone marrow plasma cell percentages ( $P=0.003$ ) and higher hemoglobin levels ( $P=0.049$ ) compared to the Low TyG group. No significant differences were found in demographic data, M protein types, or standard staging systems (DS, ISS, R-ISS). Notably, the High TyG group showed a higher proportion of patients in the "Low risk" category of the R2-ISS system, though this difference was not statistically significant ( $P=0.097$ ).
Survival Analysis: Kaplan-Meier analysis demonstrated that the High TyG group had significantly lower OS and PFS rates compared to the Low TyG group (Log-rank $P < 0.05$ for both).
Multivariate Cox Regression:
- Overall Survival (OS): The High TyG index was identified as an independent risk factor for poor OS ($HR = 78.311$, 95% CI: 3.991–1536.465, $P = 0.004$ ). The authors note the extremely wide confidence interval suggests substantial uncertainty due to the small sample size.
- Progression-Free Survival (PFS): The association between the TyG index and PFS did not reach statistical significance in the multivariate model ( $P = 0.079$ ). Renal function status was the only independent risk factor identified for PFS.

Significance and Claims
The paper claims that a higher baseline TyG index may serve as an independent risk factor for poorer Overall Survival in MM patients. The authors posit that this metabolic indicator offers prognostic information distinct from traditional tumor burden markers. They suggest that systemic metabolic inflammation, reflected by a high TyG index, may drive aggressive tumor biology and drug resistance, potentially explaining the "dissociation" observed between low tumor burden indicators and poor outcomes in some patients.

However, the authors maintain a modest tone regarding these findings. They explicitly acknowledge that the study is limited by its single-center, retrospective nature and small sample size, which resulted in wide confidence intervals and limited generalizability. They state that while the TyG index warrants further investigation as a potential metabolic biomarker, the current results are suggestive rather than confirmatory. The study concludes that future large-scale prospective studies are required to validate the TyG index's role and to compare it against established staging systems.